Methods of treating cancer with an mTOR inhibitor
US12121522B2 · kind B2 · utility
0Cited by
83References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 9, 2023 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Nov 9, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.